Patients who received 400 mg certolizumab pegol every two weeks and 200 mg certolizumab pegol every two weeks had a PASI 75 response rate of 80.1% and 74.5%, respectively, compared with 7.5% for placebo-treated patients. The PASI90 response rates were 52.2%, 44.5% and 1.6%, respectively. Both certolizumab pegol results were statistically significant (P<0.0001), as were the PGA 0/1 responder rates.
Certolizumab pegol proved to be effective for treating chronic plaque psoriasis in adults across all baseline disease characteristic subgroups and demographics. Among these subgroups, 200 and 400 mg certolizumab pegol-treated patients had clinically meaningful PASI75, PA 0/1 and PASI90 responses, all of which were greater than placebo-treated patients. At Week 16, both treatment groups had clinically meaningful improvements in the signs and symptoms of psoriasis compared with placebo-treated patients.
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
References
- Eli Lilly and Company. News release: Lilly announces positive top-line Phase 3 results for Taltz (ixekizumab) in ankylosing spondylitis radiographic axial spondyloarthritis). 2018 Feb 13.
- UCB. News release: UCB advances psoriasis pipeline with positive data at American Academy of Dermatology Annual Meeting (AAD 2018). 2018 Feb 16.
- Reich K, et al. Certolizumab pegol is effective for chronic plaque psoriasis across patient subgroups: Apooled subanalysis from ongoing, Phase 3 studies (CIMPASI-1, CIMPASI-2, CIMPACT) [abstract 7692]. 2018 Feb 17.
